三级片视频播放,精品三级片在线观看,A级性爱视频,欧美+日韩+国产+无码+小说,亲子伦XX XX熟女,秋霞最新午夜伦伦A片黑狐,韩国理伦片漂亮的保拇,一边吃奶一边做边爱完整版,欧美放荡性护士videos

TIGIT （T cell immunoglobulin and ITIM domain） is an inhibitory receptor expressed on lymphocytes, including natural killer （NK） cells and various subsets of T cells such as CD4+ T cells, CD8+ T cells, and regulatory T cells. It was discovered in 2009 through genome-wide analysis aiming to identify proteins containing domain structures typical for immunomodulatory receptors. TIGIT consists of one extracellular immunoglobulin variable domain, a type I transmembrane domain, and a short intracellular domain with one immunoreceptor tyrosine-based inhibitory motif （ITIM） and one immunoglobulin tyrosine tail （ITT）-like motif. Its main ligand is CD155, also known as poliovirus receptor （PVR）, but it can also bind to CD112 and CD113 with lower affinity. TIGIT plays a significant role in down-regulating T cell and NK cell functions by interacting with these ligands expressed on antigen-presenting cells or tumor cells. This interaction inhibits immune cell responses at multiple steps of the cancer-immunity cycle, such as impairing T cell priming by dendritic cells, preventing tumor cell killing by NK cells and cytotoxic T cells, and enhancing the immune suppressive activity of regulatory T cells. Therefore, TIGIT has emerged as a major target in cancer immunotherapy. Several monoclonal antibodies that block the inhibitory activity of human TIGIT have been developed, and clinical trials are ongoing to investigate TIGIT blockade as a monotherapy or in combination with anti-PD1/PD-L1 antibodies for the treatment of patients with advanced solid malignancies.